| Budget Amount *help |
¥46,930,000 (Direct Cost: ¥36,100,000、Indirect Cost: ¥10,830,000)
Fiscal Year 2018: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2017: ¥8,190,000 (Direct Cost: ¥6,300,000、Indirect Cost: ¥1,890,000)
Fiscal Year 2016: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
Fiscal Year 2015: ¥23,010,000 (Direct Cost: ¥17,700,000、Indirect Cost: ¥5,310,000)
|
|---|
| Outline of Final Research Achievements |
Functional interaction based on making a complex between TRPV4 with high Ca2+ permeability and Ca2+-activated chloride channel, anoctamin 1 was found to be involved in the saliva and tear secretion. And the interaction between TRPV1 and anoctamin 1 was clarified to cause enhancement of nociceptive signals in mouse sensory neurons. Furthermore, a new chemical inhibiting both TRPV1 and anoctamin 1 was found through the screening. The chemical would be a seed chemical for the development of novel analgesic agents. We also identified novel TRPA1 agonists and found that TRPA1 is activated directly by membrane stretch. Oxidation of TRPM2 by redox signals was found to be involved in the insulin secretion from mouse pancreatic β-cells. Crotamiton, a kind of anti-itch agent, was found to inhibit TRPV4. Mutation of TRPV6 was found to cause Transient Neonatal Hyperparathyroidism in human.
|
